Patent 11910787 was granted and assigned to Regeneron Pharmaceuticals on February, 2024 by the United States Patent and Trademark Office.
Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.